Clinical and experimental studies of cancer. We are running a randomized clinical trial on local treatment of breast cancer liver metastases and participate in several trials in national and international collaborations. In our lab, we study the MAPK signaling pathway and develop a model i C. elegans to identify novel treatments of cancer.
Head of project
Oskar HemmingssonAssociate professor, senior consultant (attending) physician, other position
Cancer progression is often driven by oncogenic mutations in the MAPK signalling pathway. Our group studies BRAF- and KRAS-activated cancer to explore targets to circumvent drug resistance and to find novel treatments. Currently, we focus on the tumour suppressor LRIG1 in relation to BRAF inhibitor resistance in malignant melanoma. We take advantage of the biobanks in Umeå in order to confirm results from in vitro cell culture studies in a patient material. Our group has experience from the model organism C. elegans and we recently equipped our lab for nematode research. We develop the C. elegans in vivo model to explore novel targets to block MAPK-driven cancer. https://www.umu.se/en/wallenberg-centre-for-molecular-medicine/research/wcmm-associerade-forskare/oskar-hemmingsson/
In a second project we test a novel concept of surface microdialysis to evaluate perioperative liver metabolism.